Home > Insider Trading > Filing (0001144204-17-018725)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1054274	Alliqua Biomedical Inc.	ALQA	Surgical & Medical Instruments & Apparatus (3841)	582349413

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1172343	T Mark Wagner	C/O Alliqua Biomedical, Inc. 1010 Stony Hill Road Yardley PA 19067		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-04-03	62,500	$0.40	70,500	No	4	P	Direct
Common Stock	Acquisiton	2017-03-21	75,876	$0.67	323,802	No	4	J	Indirect	By 2003 Revocable Trust of Mark Wagner

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	J	Indirect	By 2003 Revocable Trust of Mark Wagner

Footnotes

The reported shares are owned directly by 2003 Revocable Trust of Mark Wagner dated April 23, 2003 (the "Wagner Trust"). Mark Wagner is the trustee and deemed to have a pecuniary interest in, and therefore to be the beneficial owner of, the shares held by the Wagner Trust. On March 21, 2017, the Wagner Trust became entitled to receive 75,876 shares of the Issuer's common stock pursuant to an earn-out provision in the merger agreement pursuant to which the Issuer acquired all outstanding equity interest of Celleration, Inc. ("Celleration").
The merger agreement provided that the equity holders of Celleration would receive additional shares of the Issuer's common stock, for no additional consideration, if Celleration's revenue exceeded the revenue target for the fiscal year ending December 31, 2016, as set forth in the merger agreement. Celleration's revenue exceeded the revenue target for 2016, as a result of which Celleration's former equity holders, including the Wagner Trust, acquired additional shares, as determined on March 21, 2017, pursuant to the formula set forth in the merger agreement.
For purposes of determining the number of shares issuable pursuant to the earn-out right, the formula set forth in the merger agreement provided that the Issuer's common stock would be valued at $0.67, based on the 45 trading day volume weighted average price as of the trading day prior to December 31, 2016.